Epix Pharmaceuticals, Inc. Announces the May 28, 2010 Auction Sale of Its MRI Imaging Intellectual Properties

By Finn Warnke Gayton, PRNE
Sunday, April 4, 2010

WELLESLEY HILLS, Massachusetts, April 5, 2010 - Joseph F. Finn, Jr., C.P.A. ("Finn"), Assignee for the Benefit of
Creditors of Epix Pharmaceuticals, Inc. ("Epix"), announced today that the
MRI imaging intellectual properties will be auctioned on May 28, 2010. The
assets of Epix were transferred to him on July 20, 2009 and he is liquidating
them for the benefit of Epix creditors. He recently reached an agreement with
Bayer Schering Pharma that permits the sale of the MRI imaging programs.

The family of gadolinium-based imaging programs consists of: 1) MS-325
(gadofosveset trisodium), commercial MRA imaging agent, currently marketed as
Ablavar(R) in the US by Lantheus Medical Imaging and formerly marketed as
Vasovist(R), in Europe and other countries by Bayer Schering Pharma. The
MS-325 commercial rights for sale include Europe, Switzerland and other
regions outside the US, Canada, Puerto Rico and Australia; 2) EP-2104R, a
fibrin binding MRI imaging agent in Phase 2 clinical development for clot
detection; and 3) EP-3600, a collagen binding MRI imaging agent in
preclinical development for myocardial perfusion. Bidders may bid on any
combination of the three or all three.

Persons interested in bidding must sign a Confidentiality Disclosure
Agreement ("CDA") obtained from Finn's Office -
IPSALESERVICES@FINNWARNKEGAYTON.COM or 781-237-8840. They will then receive a
bid package and access to an electronic data room.

About Joseph F. Finn, Jr., C.P.A.

Joseph F. Finn, Jr., C.P.A. is the owner of the firm, Finn, Warnke &
Gayton, Certified Public Accountants of Wellesley Hills, Massachusetts. He
works primarily in the area of management consulting for distressed
enterprises, bankruptcy accounting and related matters, such as assignee for
the benefit of creditors and liquidating agent for a corporation. He has been
involved in a number of loan workouts and bankruptcy cases for thirty-five
(35) years. His most recent Assignments for the Benefit of Creditors in the
biotech field include Spherics, Inc., ActivBiotics, Inc. and Prospect
Therapeutics, Inc.

For further information, please contact Joseph F. Finn, Jr., C.P.A. at

Joseph F. Finn, Jr., C.P.A., Finn, Warnke & Gayton, +1-781-237-8840, IPSALESERVICES at FINNWARNKEGAYTON.COM

will not be displayed